Abstract 3443
Background
Breast cancer is the most common cancer in women. Most breast tumors are ER(+)/hormone-dependent, this makes it possible to treat them with tamoxifen and other SERM/SERD drugs. Combination treatment of tamoxifen with novel drugs provides an efficient way for reduction of the drug concentration. The aim of the work was to obtain novel less toxic oligomycin derivatives for combinatorial treatment with tamoxifen.
Methods
Oligomycin A was produced at BIOAN (Moscow, Russia) using Streptomyces avermitilis NIC B62. The oligomycin derivatives were synthesized from oligomycin A. MCF-7 breast cancer cell line and MCF-10A human mammary epithelial cell line were obtained from the ATCC collection. Hormone-resistant subline was developed by long-term treatment of MCF-7 line with tamoxifen. Antiproliferative activity was measured by MTT.
Results
A series of less toxic oligomycin A derivatives, selectively modified at the C-33 position of the side chain, was synthesized, and their activity against hormone-dependent breast cancer cells was tested. Lead compound, a (33S)-diastereomer of oligomycin A (epi-oligomycin A), was chosen, which showed high activity towards MCF-7 breast cancer cells and MCF-7/TR hormone-resistant cells. Low doses of tamoxifen and epi-oligomycin A, which had no significant effects on the growth of MCF-7 cells, were evaluated. In combination, low doses of tamoxifen and epi-oligomycin A caused a significant antiproliferative effects on MCF-7 cells. Moreover, it was possible to return the sensitivity of hormone-resistant subline to tamoxifen by epi-oligomycin A treatment. Non-malignant epithelial cells, MCF-10A, were less sensitive to epi-oligomycin A.
Conclusions
Novel epi-oligomycin A enhances response to tamoxifen, which allows for reduction of the effective drug concentration. Combinatorial strategy with epi-oligomycin A may hold promise in development of therapies against breast tumours, including those with acquired resistance to the hormonal treatment. The research is supported by Russian Science Foundation (chemistry, agreement 15-15-00141) and the Russian Foundation for Basic Research (biology, 18-015-00422).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation (chemistry, agreement 15-15-00141) and the Russian Foundation for Basic Research (biology, 18-015-00422).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1842 - Immunological impact of surgery in NSCLC patients
Presenter: Akitoshi Yanagihara
Session: Poster Display session 1
Resources:
Abstract
4124 - The prognostic value of selected immunological panel in predicting the prognosis of early-stage resectable non-small cell lung cancer
Presenter: Sha Zhao
Session: Poster Display session 1
Resources:
Abstract
4468 - Genomic Heterogeneity and Clonality Analysis of Multiple synchronous lung cancers (MSLCs)
Presenter: Fachen Zhou
Session: Poster Display session 1
Resources:
Abstract
5547 - Analysis of immunosuppressive factors produced by tumorspheres in NSCLC. Prognostic value of Galectin-3 in adenocarcinoma
Presenter: Susana Torres Martinez
Session: Poster Display session 1
Resources:
Abstract
1658 - Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small-cell lung cancer (NSCLC) after complete tumour resection
Presenter: Masahiro Tsuboi
Session: Poster Display session 1
Resources:
Abstract
1535 - EGFR mutation is not a prognostic factor in completely resected lymph node–negative pulmonary adenocarcinoma (LNNPA)
Presenter: Nussara Leeladejkul
Session: Poster Display session 1
Resources:
Abstract
3262 - Prognostic significance of elements of the adaptive immunity in the microenvironment of early-stage non small cell lung cancer
Presenter: Aliki Liakea
Session: Poster Display session 1
Resources:
Abstract
4643 - Combined immunoscore for prognostic stratification of early stage NSCLC patients
Presenter: Giulia Pasello
Session: Poster Display session 1
Resources:
Abstract
4819 - Radiation-induced lung injury and misdiagnosis rate after SBRT
Presenter: Xiaolong Fu
Session: Poster Display session 1
Resources:
Abstract
681 - Significance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer
Presenter: Gouji Toyokawa
Session: Poster Display session 1
Resources:
Abstract